Personalis, Inc.
PSNLPersonalis is a cancer genomics company that provides advanced testing services for precision oncology and personalized medicine.
Earnings
Next report
Nov 3, 2026 (Tomorrow)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Personalis is a cancer genomics company that provides advanced testing services for precision oncology and personalized medicine. The company utilizes high-sensitivity sequencing technology to help physicians detect minimal residual disease, monitor therapy response, and select targeted treatments. Their platform also supports pharmaceutical companies in biomarker discovery and the development of personalized cancer therapies.
A leader in ultrasensitive liquid biopsy for minimal residual disease (MRD) detection, leveraging a proprietary tumor-informed approach that identifies cancer recurrence earlier than traditional imaging.
FAQ
- What is Personalis, Inc.'s market cap?
- Personalis, Inc. (PSNL) has a market capitalization of $1.7B and trades on NASDAQ.
- What is Personalis, Inc.'s revenue and profitability?
- Personalis, Inc. generated $69.7M in trailing twelve-month revenue with a net loss of $107.2M, representing a net margin of -153.8%. Gross margin stands at 12.7%, with free cash flow of -$101.0M. The latest reported period is Q2 2026.
- Who are Personalis, Inc.'s competitors?
- Personalis, Inc.'s key competitors include NeoGenomics, Biodesix, Inc. Common Stock, Guardant Health, and others. These companies compete in similar markets and product categories.
- Who does Personalis, Inc. partner with?
- Personalis, Inc.'s notable partners include Tempus, Moderna, Natera, and others.
- Where is Personalis, Inc. headquartered?
- Personalis, Inc. is headquartered in United States of America and employs approximately 225 people. It has been publicly traded since 2019.
